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Summary
Purpose: We evaluated whether time-dependent procedural improvement was independently
associated with reduction in atrial ﬁbrillation (AF) recurrences or periprocedural complications
in patients who underwent catheter ablation for AF at a single medium-volume center.
Methods: A total of 208 consecutive patients who underwent AF ablation from June 2006 to
June 2009 were enrolled. All procedures were performed by an experienced operator, and the
ablation protocol, devices, and equipment remained unchanged throughout the study period.
The study period was divided into quarters (1—4 Q) to include the same number of patients
within each quarter. The incidence of AF recurrences or periprocedural complications requiring
a prolonged hospital stay or surgical intervention was retrospectively compared across the
quarters.
Results: During follow-up (15± 3 months), we observed 26 (13%) AF recurrences (27% in 1Q, 15%
in 2Q, 6% in 3Q, 2% in 4Q; 1Q vs. 3Q, p = 0.0035; 1Q vs. 4Q, p = 0.0003; 2Q vs. 4Q, p = 0.013) and
15 (7%) periprocedural complications (12% in 1Q, 8% in 2Q, 6% in 3Q, 4% in 4Q), both of which
declined progressively over time. Multiple logistic regression analysis revealed that 1Q, but
not any other patient background parameters, was an independent predictor of the incidence
of AF recurrence or periprocedural complications (odds ratio, 2.45; 95% conﬁdence interval,
1.19—5.20; p = 0.015).
Conclusions: The time period when the procedure was performed signiﬁcantly inﬂuenced the AF
ablation outcome, indicating that operators in medium-volume centers should be committed to
providing gratifying outcomes particularly early in the institutional experience with AF ablation.
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ntroduction
uring the past decade, catheter ablation for atrial ﬁbrilla-
ion (AF) has rapidly evolved [1]. However, a standardized
pproach and facility criterion for providing effective and
afe outcomes has not been established [2], and interfacility
isparities in AF recurrence after ablation or procedure-
elated complications have been observed with higher
requencies reported in small- or medium-volume centers
han in high-volume centers [3,4]. This suggests an impor-
ance of the operative experience and the proﬁciency of
perators, which seems to be a rarely discussed issue. To
hat end, we hypothesized that unfavorable AF ablation
utcomes depended more on operator skill than on patient
haracteristics in small- or medium-volume centers that had
ewly started AF ablation. The aim of the present study was
o evaluate whether time-dependent procedural improve-
ents were independently associated with a reduction in
F recurrences or periprocedural complications in patients
ho underwent AF ablation.
ethods
tudy population
he present study included 208 consecutive patients with
rug-refractory AF who had undergone catheter ablation at
iroshima University Hospital from June 2006 to June 2009.
onparoxysmal AF was deﬁned as persistent AF or perma-
ent AF. Exclusion criteria were age >75 years, hepatic or
enal disease, left ventricular dysfunction with an ejection
raction of <35%, malignancy, and prior AF ablation. Class I
r IV antiarrhythmic drugs (AADs) were discontinued 5 half
ives before AF ablation and amiodarone was discontinued
weeks prior to the procedure. Adequate oral anticoag-
lation therapy (international normalized ratio 2—3) was
dministered no less than 1 month before the procedure
nd was continued throughout the periprocedural period
ithout interruption. Patients underwent transesophageal
chocardiography and cardiac computed tomography prior
o the procedure. Written informed consent was obtained
rom all patients, and the study protocol was approved by
he research committee of our institution.
blation procedure
etails of the double Lasso catheter-guided extensive encir-
ling pulmonary vein isolation (EEPVI) performed in the
resent study have been described previously [5]. In brief,
6-French decapolar catheter (St. Jude Medical, St. Paul,
N, USA) was positioned in the coronary sinus for record-
ng and atrial pacing. After transseptal catheterization,
wo 7-French decapolar Lasso catheters (Biosense Webster,
iamond Bar, CA, USA) were placed within the ipsilateral
uperior and inferior pulmonary veins (PVs) guided by selec-
ive PV angiography. After constructing three-dimensional
lectroanatomical maps using a non-ﬂuoroscopic navigation
ystem (CARTO, Biosense Webster), circumferential abla-
ion lines were created around the left- and right-sided
psilateral PVs using a 4.0mm tip temperature controlled
T
s
e
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on-irrigated catheter (Navistar, Biosense Webster) at a
aximum power of 30W and a maximum electrode—tissue
nterface temperature of 55 ◦C. The EEPVI end point was the
reation of a bidirectional conduction block from the left
trium (LA) to PVs. An additional linear lesion connecting
he superior aspects of the left and right upper PV isola-
ion lesions was created for patients with nonparoxysmal
F [6]. If AF was still present after LA ablation, transtho-
acic cardioversion was performed to restore sinus rhythm.
inally, the cavotricuspid isthmus was ablated with an end
oint of bi-directional conduction block using a 4.0mm tip
emperature controlled non-irrigated catheter (EPT; Boston
cientiﬁc Corporation, Natick, MA, USA) at a maximum
ower of 40W and a maximum electrode—tissue interface
emperature of 60 ◦C. Intravenous heparin was administered
o maintain an activated clotting time of 300—400 s during
he procedure. All procedures were performed by the same
xperienced physician, and the ablation protocol, devices,
nd equipment remained unchanged throughout the study
eriod.
ollow-up
lass I AADs for the patient with paroxysmal AF and amio-
arone for those with nonparoxysmal AF were started
imultaneously with hospital discharge on the next day
fter the procedure. A blanking period of 3 months was
mployed following the procedure, such that recurrences
uring this time were not considered [7]; patients were fol-
owed up at the outpatient clinic 3, 6, 9, and 12 months
fter the procedure. We performed 12-lead electrocardio-
raphy and 24-h Holter monitoring at each clinic visit, and
atients also underwent intensive questioning regarding any
rrhythmia-related symptoms. In principle, all AADs and oral
nticoagulants were discontinued if the patients remained
ree of AF for 3 months (the end of the initial blanking
eriod). However, long-term warfarin treatment was contin-
ed for the patients with a CHADS2 score of ≥2 even though
hey had no recurrence of AF. AF recurrence was deﬁned
s recurrence of symptoms suggestive of tachycardia and an
pisode of AF documented on the 12-lead electrocardiogram
r 24-h Holter monitoring during the follow-up period. When
F recurred, sinus rhythm was restored using transthoracic
ardioversion or intravenous application of AADs.
nd points
he end points of the present study were an AF recurrence
hat occurred more than 6 months after the procedure or
he incidence of periprocedural complications deﬁned as
hose that were likely to result in permanent injury, pro-
ongation of hospitalization, requirement of intervention for
reatment, or death [4].
tatistical analysis and study protocolhe study period was divided into quarters to include the
ame number of patients who underwent AF ablation within
ach quarter; 1st quarter (1Q) (from June 2006 to Octo-
er 2007, n = 52), 2nd quarter (2Q) (from November 2007
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Table 1 Baseline characteristics of the subjects in each quarter.
Variables 1Q n = 52 2Q n = 52 3Q n = 52 4Q n = 52
Age (years) 61± 10 60± 11 62± 10 62± 10
Men 44 (85%) 41 (79%) 40 (77%) 44 (85%)
Body mass index (kg/m2) 23.9± 2.7 22.8± 2.5*,† 24.3± 3.3* 24.0± 2.6†
Nonparoxysmal AF 10 (19%)‡ 17 (33%) 18 (35%) 19 (37%)‡
Duration of AF (years) 6.4± 4.5 4.7± 5.9 4.7± 5.5 5.5± 6.6
Antiarrhythmic drugs 39 (75%) 31 (60%) 36 (69%) 33 (63%)
Amiodarone 1 (2%)§,|| 7 (13%)§ 6 (12%) 9 (17%)||
Hypertension 22 (42%)¶ 29 (56%) 30 (58%) 32 (62%)¶
Diabetes 4 (8%) 7 (13%) 4 (8%) 4 (21%)
Coronary artery disease 3 (6%) 0 0 2(4%)
Structural heart disease 6 (12%)** 14 (27%)**,†† 4 (8%)†† 9 (17%)
Left atrial diameter (mm) 40± 7 39± 7 39± 7 41± 6
Left ventricular ejection fraction (%) 64± 9‡‡ 63± 10 64± 7§§ 60± 6‡‡,§§
AF, atrial ﬁbrillation. 1Q = 1st quarter (from June 2006 to October 2007); 2Q = 2nd quarter (from November 2007 to August 2008); 3Q = 3rd
r (for
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cutaneous drainage, 3 LA perforation cases, 3 pericarditis
cases, 1 case of transient ischemic attack, and 1 case of cer-
vical hematoma (requiring no surgical repair or transfusion).
While all patients with these complications had prolongedquarter (from September 2008 to February 2009); 4Q = 4th quarte
*2Q vs. 3Q, p = 0.0074; †2Q vs. 4Q, p = 0.031; ‡1Q vs. 4Q, p = 0.049
**1Q vs. 2Q, p = 0.047; ††2Q vs. 3Q, p = 0.0095; ‡‡1Q vs. 4Q, p = 0.0
to August 2008, n = 52), 3rd quarter (3Q) (from Septem-
ber 2008 to February 2009, n = 52), and 4th quarter (4Q)
(from March 2009 to June 2009, n = 52). Clinical charac-
teristics and end points for subjects in each quarter were
presented using frequencies for categorical variables and
means with standard deviations for continuous variables.
Differences in clinical characteristics and the frequencies of
AF recurrences or periprocedural complications across the
quarters were examined using Pearson’s chi-square test for
categorical variables and t-tests for continuous variables.
Kaplan—Meier analysis was used to assess the time taken for
AF recurrence to occur. The log-rank test was used to com-
pare AF-free survival across the quarters. Univariate and
multivariate logistic regression analyses were performed
using various clinical factors to determine predictors of AF
recurrence or periprocedural complications. Variables with
a p-value of <0.2 in the univariate analysis were included
in multivariate models. Statistical analyses were performed
using JMP software version 8.0 (SAS Institute Japan, Tokyo,
Japan). For all analyses, p < 0.05 was considered statistically
signiﬁcant.
Results
Baseline characteristics
The characteristics of all study subjects (4 groups) are sum-
marized in Table 1. The prevalence of nonparoxysmal AF
and hypertension was signiﬁcantly higher in 4Q than in 1Q
(nonparoxysmal AF 37% vs. 19%; p = 0.049; hypertension 62%
vs. 42%; p = 0.049). Body mass index (BMI) was signiﬁcantly
lower in 2Q than in 3Q and 4Q (2Q vs. 3Q, 22.8± 2.5 vs.
24.3± 3.3; p = 0.0074, 2Q vs. 4Q, 22.8± 2.5 vs. 24.0± 2.6;
p = 0.031). Although there was no difference in the fre-
quency of preprocedural use of any AAD across the quarters,
that of amiodarone was signiﬁcantly lower in 1Q than 2Q and
4Q (1Q vs. 2Q, 2% vs. 13%; p = 0.027; 1Q vs. 4Q, 2% vs. 17%;
p = 0.0078). The prevalence of structural heart disease was
F
l
pm March 2009 to June 2009).
vs. 2Q, p = 0.027; ||1Q vs. 4Q, p = 0.0078; ¶1Q vs. 4Q, p = 0.049;
§3Q vs. 4Q, p = 0.0025.
igniﬁcantly higher in 2Q than 1Q and 3Q (2Q vs. 1Q, 27% vs.
2%; p = 0.047; 2Q vs. 3Q, 27% vs. 8%; p = 0.0095). Lastly, left
entricular ejection fraction (LVEF) was signiﬁcantly lower
n 4Q than in 1Q and 3Q (4Q vs. 1Q, 60± 6% vs. 64± 39%;
= 0.012; 4Q vs. 3Q, 60± 6% vs. 64± 7%; p = 0.002) (Table 1).
F recurrences and periprocedural complications
e observed 26 AF recurrences (13%) during 15± 3 months
f follow-up; these recurrences signiﬁcantly and progres-
ively decreased over time (27% in 1Q, 15% in 2Q, 6% in
Q, 2% in 4Q; 1Q vs. 3Q, p = 0.0035; 1Q vs. 4Q, p = 0.0003;
Q vs.4Q, p = 0.013) (Table 2). Similarly, the Kaplan—Meier
urves showed that AF recurrence-free rate increased mono-
onically from 1Q to 4Q (p = 0.0005) (Fig. 1). The following
5 (7%) periprocedural complications occurred during the
ollow-up period: 7 cardiac tamponade cases requiring per-igure 1 Kaplan—Meier estimates of the time to atrial ﬁbril-
ation (AF) recurrence after ablation across quartiles of study
eriod.
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Table 2 The frequency of atrial ﬁbrillation (AF) recurrences and periprocedural complications in each quarter.
1Q
n = 52
2Q
n = 52
3Q
n = 52
4Q
n = 52
AF recurrences 14 (27%)*,† 8 (15%)‡ 3 (6%)* 1 (2%)†,‡
Periprocedural
complications
6 (12%) 4 (8%) 3 (6%) 2 (4%)
3 Cardiac tamponades 2 Cardiac tamponades 2 Pericarditises 2 Cardiac tamponades
2 Left atrium perforations 1 Left atrium perforation 1 Cervical hematoma
1 Transient ischemic attack 1 Pericarditis
AF recurrences or
complications
14 (27%)§,|| 9 (17%)¶ 6 (12%)§ 2 (4%)‖,¶
arter
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t1Q= 1st quarter (from June 2006 to October 2007); 2Q = 2nd qu
September 2008 to February 2009); 4Q = 4th quarter (form March
*1Q vs. 3Q, p = 0.0035; †1Q vs. 4Q, p = 0.0003; ‡2Q vs.4Q, p = 0.013
ospital stays, they achieved full rehabilitation without
ermanent injury. In addition, 10 of 15 subjects who expe-
ienced periprocedural complications subsequently also
eported AF recurrence. Even though not statistically signif-
cant, periprocedural complications tended to decline over
ime (12% in 1Q, 8% in 2Q, 6% in 3Q, 4% in 4Q) (Table 2).
e also observed a gradual decrease in procedural duration
1Q, 296± 94min; 2Q, 237± 45min; 3Q, 219± 40min; 4Q,
15± 48min; 1Q vs. 2Q, p < 0.0001; 1Q vs. 3Q, p < 0.0001;
Q vs. 4Q, p < 0.0001).redictors of incidence of AF recurrence or
eriprocedural complications
nivariate logistic regression analysis revealed that 1Q was
igniﬁcantly associated with the incidence of AF recurrences
p
s
o
s
s
Table 3 Predictors of incidence of atrial ﬁbrillation (AF) recurre
variate analyses.
Variables Univariate
OR (95% CI)
Age > 65 years 0.89 (0.59-1.33)
Men 1.11 (0.69-1.96)
Body mass index > 25 kg/m2 1.34 (0.90-1.98)
Nonparoxysmal AF 1.23 (0.82-1.82)
Duration of AF > 5 years 1.36 (0.90-2.03)
Hypertension 1.28 (0.87-1.93)
Diabetes 1.20 (0.67-1.97)
Structural heart disease 0.87 (0.46-1.46)
Left atrial diameter > 45mm 1.51 (0.93-2.36)
Left ventricular ejection fraction < 55% 0.70 (0.34-1.23)
Procedural duration > 250min 1.33 (0.90-1.96)
Procedural period
1Q 2.6 (1.38-5.10)
2Q 1.55 (0.72-3.33)
3Q 0.92 (0.41-1.96)
4Q Reference
OR, odds ratio; CI, conﬁdence interval. 1Q = 1st quarter (from June 2
August 2008); 3Q = 3rd quarter (from September 2008 to February 2009(from November 2007 to August 2008); 3Q = 3rd quarter (from
to June 2009).
vs. 3Q, p = 0.047; ||1Q vs. 4Q, p = 0.0011; ¶2Q vs. 4Q, p = 0.023.
r periprocedural complications (odds ratio, 2.6; 95% con-
dence interval, 1.38—5.10; p = 0.0036). After adjustments
or BMI, AF duration, LA diameter, and procedural duration,
Q remained signiﬁcantly and independently associated with
he occurrence of unfavorable outcomes (odds ratio, 2.45;
5% conﬁdence interval, 1.19—5.20; p = 0.015) (Table 3).
iscussion
his study was unique in that the end point was a sum of
he incidence of AF recurrences and periprocedural com-
lications, and was deﬁned based on our assumption of a
igniﬁcant association between them. Actually, two-thirds
f the patients who experienced in-hospital complications
ubsequently also reported AF recurrences, possibly because
ome ablation procedures could not be completed because
nce or periprocedural complications in univariate and multi-
Multivariate
p-Value OR (95% CI) p-Value
0.59
0.68
0.14 1.29 (0.81-2.04) 0.27
0.3
0.13 1.22 (0.80-1.87) 0.35
0.22
0.51
0.63
0.077 1.24 (0.69-2.13) 0.45
0.27
0.15 0.89 (0.55-1.41) 0.63
0.0036 2.45 (1.19-5.20) 0.015
0.27 1.45 (0.70-3.00) 0.25
0.83 0.92 (0.40-2.01) 0.84
Reference
006 to October 2007); 2Q = 2nd quarter (from November 2007 to
); 4Q = 4th quarter (form March 2009 to June 2009).
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of critical complications such as cardiac tamponade encoun-
tered during the procedure. This study showed a signiﬁcantly
progressive reduction in AF recurrence and periprocedural
complications over time. Since AF ablation is technically
more difﬁcult and is associated with greater risks com-
pared with other ablation procedures, it is required that
operators display a high level of skill and considerable expe-
rience when performing this procedure [8]. Therefore, given
that the operator, the procedural methods, and the devices
and equipment used at our institute remained unchanged
throughout the study period, the progressive improvement
in AF ablation outcomes suggests an enhanced technical
ability over time, highlighting the results from the study
conducted by Spragg et al. [9]. The following have been
reported to be independent predictors of AF recurrence:
nonparoxysmal AF [10—13], decreased LVEF [14—16], LA
enlargement [17—20], longer AF symptom duration [13,14],
hypertension [13,19,20], structural heart disease [21], and
obesity [14,22]. In addition, several investigators have
shown that older age [4,23], coronary artery disease [4,24],
obesity [4], and congestive heart failure [23] are inde-
pendently associated with in-hospital complications. In the
present study, some risk factors such as nonparoxysmal
AF, increased BMI, hypertension, and decreased LVEF were
most frequently observed in 4Q; however, unfavorable AF
ablation-related outcomes were least likely in the same
quarter. This discrepancy and the gradual decrease in proce-
dural duration support our hypothesis that an improvement
in the operator’s technical ability to perform AF ablation
resulted in a signiﬁcant reduction in the incidence of unfa-
vorable outcomes.
Unlike prior investigations [4,10—24], only the earliest
stage when AF ablation was newly started, rather than any
of the known risk factors for AF recurrence or periprocedu-
ral complications, predicted the sum of these unfavorable
outcomes in the present study, suggesting that the success
of AF ablation possibly depended on the skill of the med-
ical personnel to a greater extent than it did on patient
characteristics in small- or medium-volume centers. Possi-
ble explanations for this difference from previous studies
are as follows: (1) few studies have focused on competence
of the medical personnel as a predictor of ablation-related
unfavorable outcomes; (2) the end point of the present study
was the sum of the incidence of AF recurrences and peripro-
cedural complications; (3) the same operator performed all
ablation procedures throughout the study period at our insti-
tute; (4) we started enrolling patients for our study as soon
as AF ablation procedure was initiated at our facility.
In the present study, the AF-free rate at 6 months was
>90% in 3Q and 4Q after applying only EEPVI and LA roof
linear ablation and fairly high, nonetheless, a decline in
this percentage was expected over time due to a certain
number of AF recurrences in the later phase [25]. This ﬁnd-
ing suggests that an excellent result can be achieved using
relatively simple ablation methods if the procedures are per-
formed by the operator with experience of >100 procedures
of AF ablation.The rate of overall periprocedural complications in
the present study was comparable with or slightly higher
than those previously reported in a few large series stud-
ies [3,4,9,23,24]. However, while vascular complication
is known to be one of the most frequent complicationse centers 267
3,4,9,23,24], we encountered only one cervical hematoma
ossibly because none of the patients in our study were
orbidly obese (BMI >40 kg/m2), or because an experienced
perator performed all punctures throughout the study
eriod; a puncture is often done by a less-trained physician
n a considerable number of facilities.
tudy limitations
his study had several limitations. First, this was a single-
enter study with a small number of study subjects, thus
imiting the statistical power. Second, a gradual reduction
n the incidence of AF recurrence or periprocedural com-
lications over time might not necessarily be explained
y improved procedural ability of the medical personnel
lone. Third, early and very late AF recurrences were not
ssessed because of a 3-month initial blanking period and
he cessation of follow-up after the 12-month clinical visit,
espectively. Despite these limitations, to the best of our
nowledge, this is the ﬁrst study that has included the skill of
edical personnel performing AF ablation as a determinant
f clinical outcomes. To establish further clinical evidence, a
ulticenter trial of small- or medium-volume centers with
onsideration to the inﬂuence of the skill of the medical
ersonnel on AF ablation outcomes should be conducted.
linical implications
urrently, the number of the centers starting up AF abla-
ion has markedly increased along with increased awareness
f its validity around the world. The clinical implication of
he present study is that our ﬁndings can be regarded as
n encouragement as well as a warning to such institutes:
s shown in the present study, the outcomes of AF ablation
re likely to be unsatisfactory regardless of patient char-
cteristics for the initial period in medium-volume centers.
herefore, medical personnel should be suitably and satis-
actorily trained before starting AF ablation and must sustain
nventive approaches to end up gratifying outcomes after
tarting.
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